APMD Apnimed, Inc. - Common Stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Sep 8, 2026APMD Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
APMD Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | APMD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | -0.6 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | APMD | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | -0.2 | · | · | · | |
| Current Ratio (MRQ) | 5.2 | · | · | · | |
| Long-Term Debt / Equity (MRQ) | -0.2 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Sep 8, 2026 | $-0.34 | $-0.52 | 34.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q2 2026 |
|---|---|---|
| Revenue | $12M | |
| R&D Expense | $10M | |
| SG&A Expense | $13M | |
| Operating Expenses | $24M | |
| Operating Income | $-12M | |
| Other Non-op | $-3M | |
| Pretax Income | $126M | |
| Income Tax | $0 | |
| Net Income | $126M | |
| Shares (Basic) | 4,797,152 | |
| Shares (Diluted) | 32,353,048 | |
| EBITDA | $-12M |
Balance Sheet
| Metric | Trend | Q2 2026 |
|---|---|---|
| Cash & Equivalents | $173M | |
| Receivables | $690.0K | |
| Prepaid Expense | $5M | |
| Current Assets | $185M | |
| PP&E (Net) | $53.0K | |
| PP&E (Gross) | $117.0K | |
| Accum. Depreciation | $64.0K | |
| Other Non-current Assets | $24.0K | |
| Total Assets | $195M | |
| Accounts Payable | $7M | |
| Current Liabilities | $36M | |
| Capital Leases | $485.0K | |
| Total Liabilities | $126M | |
| Total Debt | $40M | |
| Common Stock | $1.0K | |
| Paid-in Capital | $28M | |
| Retained Earnings | $-204M | |
| Stockholders' Equity | $-176M | |
| Liabilities + Equity | $195M | |
| Shares Outstanding | 4,801,823 |
Profitability
| Metric | Trend | Q2 2026 |
|---|---|---|
| Operating Margin | -96.9% | |
| Net Margin | 1042.5% | |
| Pretax Margin | 1044.0% | |
| EBITDA Margin | -96.9% | |
| ROA | 128.9% | |
| ROE | -143.0% | |
| ROIC | 8.6% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 |
|---|---|---|
| Current Ratio | 5.2 | |
| Quick Ratio | 4.9 | |
| Debt / Equity | -0.2 | |
| LT Debt / Equity | -0.2 |
Efficiency
| Metric | Trend | Q2 2026 |
|---|---|---|
| Asset Turnover | 0.1 | |
| Receivables Turnover | 35.0 |
Per Share
| Metric | Trend | Q2 2026 |
|---|---|---|
| Book Value / Share | $-36.69 | |
| Revenue / Share | $0.37 | |
| Cash / Share | $35.99 |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Company insiders 9 insiders · 3 officers · 6 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Kevin Robert Lind | Chief Executive Officer | Aug. 3, 2026 A | · | 0 | 0 | $0 |
| Michael B Kelly | Chief Financial Officer | Aug. 3, 2036 A | · | 0 | 0 | $0 |
| Dennis Patrick Molnar | President | Aug. 3, 2026 A | 58,014 | 0 | 0 | $0 |
| Paul R. Fonteyne | Director | Aug. 3, 2026 A | · | 0 | 0 | $0 |
| Gary Sender | Director | Aug. 3, 2026 A | · | 0 | 0 | $0 |
| Lawrence G. Miller | Director | Aug. 3, 2026 A | 88,954 | 0 | 0 | $0 |
| William A Jones JR | Director | Aug. 3, 2026 A | · | 0 | 0 | $0 |
| Paul J Sekhri | Director | Aug. 3, 2026 A | 12,500 | 1 | 0 | $200,000 |
| Morningside Venture Investments Ltd | · | Aug. 3, 2026 C | 75,624 | 1 | 0 | $5,000,000 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
APMD Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
3 analysts · 2026-10-02Mean target $50.33 +134.0%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| APMD | · | · | · | · | · | · |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| SPTX | · | · | · | · | · | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| SGP | · | · | · | · | 50.0% | · |
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | · |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.